Pacific Biosciencesの空売り状況は、投資家がPacific Biosciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Pacific Biosciences (NASDAQ:PACB) 株価情報, 空売り情報

PACIFIC BIOSCIENCES OF CALIF

Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences of California Inc

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Neutral and lowers the price target from $2 to $1.25.

News

Price Target

Analyst Ratings

PACB

Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $2.13, with a high estimate of $3.00 and a low estimate of $1.50. This current average has decreased by 27.05% from the previous average price target of $2.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1747317706_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Pacific Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$1.80</td>
<td>$1.80</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Pacific Biosciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Pacific Biosciences's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Pacific Biosciences</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>Unraveling the Financial Story of Pacific Biosciences</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Pacific Biosciences faced challenges, resulting in a decline of approximately -4.27% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacific Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1146.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Pacific Biosciences's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -142.44%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pacific Biosciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -40.17%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pacific Biosciences's debt-to-equity ratio stands notably higher than the industry average, reaching 7.63. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Pacific Biosciences Stands With Analysts

Stephens &amp; Co. analyst Mason Carrico reiterates Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Overweight and maintains $1.8 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Pacific Biosciences, Maintains $1.8 Price Target

PacBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the investigation found no improper employment practices and no material inaccuracies or omissions with respect to the cybersecurity disclosures in the Company's 2024 Form 10-K.

PacBio Independent Investigation Finds No Issues in Employment & Cybersecurity Matters

WIIM

Pacific Biosciences shares are trading lower. The company reported Q1 financial results.

Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 42.31 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $37.15 million which beat the analyst consensus estimate of $34.81 million by 6.73 percent. This is a 4.27 percent decrease over sales of $38.81 million the same period last year.

Earnings

Earnings Beats

Pacific Biosciences Q1 Adj. EPS $(0.15) Beats $(0.19) Estimate, Sales $37.15M Beat $34.81M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

PacBio&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as part of a newborn screening research program. This marks the first initiative in Asia Pacific to explore the use of PacBio's HiFi sequencing technology at population scale - an effort designed to evaluate how comprehensive genomic data can support earlier, more accurate identification of rare and treatable conditions in newborns. The collaboration highlights Thailand's growing leadership in precision medicine and offers a potential model for countries seeking to modernize newborn screening with genome-wide approaches.

PacBio Announces Strategic Collaboration To Implement PacBio HiFi Whole Genome Sequencing As Part Of Newborn Screening Research Program

On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), and Shopify Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>). 
The Palantir Trade
Ark Invest made a notable move by selling shares of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) across ARK Next Generation Internet ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#BATS">ARKW</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>). The sale involved 19,005 shares in ARKW and 3,375 shares in ARKX. With Palantir&#8217;s stock closing at $118.44, the total value of the shares sold amounted to approximately $2.65 million. Palantir has been in the spotlight due to its recent defense contracts and <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45113101/palantir-stock-is-up-55-ytd-heading-into-earnings-next-week-whats-going-on">upcoming earnings report</a> on May 5. The company has been actively involved in the TITAN program, delivering systems to the U.S. Army, which has contributed to its stock&#8217;s 55% year-to-date increase. 
The AMD Trade
Ark Invest also increased its stake in Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) through ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) and ARKW. The firm purchased 106,769 shares in ARKK and 12,349 shares in ARKW, totaling a value of approximately $11.56 million, with AMD&#8217;s stock closing at $97.35. This move comes amid industry discussions about Huawei&#8217;s development of an AI chip, <a href="https://www.benzinga.com/trading-ideas/movers/25/04/45052912/whats-going-on-with-advanced-micro-devices-stock-monday">potentially challenging competitors</a>. Despite this, AMD continues to be a key player in the semiconductor industry. Notably, Ark has made AMD purchases <a href="https://in.benzinga.com/25/04/45089384/cathie-wood-bets-against-mark-zuckerbergs-meta-ahead-of-crucial-earnings-report-loads-up-on-this-amazon-rival">throughout this week</a> so far. The company loaded up on $3.79 million worth of shares on Monday and another $747,923 worth on Tuesday.
The Shopify Trade
Ark Invest&#8217;s purchase of 12,632 shares of Shopify Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>) through its ARKW ETF reflects a strategic investment in the e-commerce sector. With SHOP&#8217;s stock closing at $95.00, the transaction was valued at approximately $1.2 million. Shopify faces new challenges due to <a href="https://www.benzinga.com/markets/25/04/44640798/trump-ends-de-minimis-exemptions-shopify-bigcommerce-and-lightspeed-face-new-headwinds">changes in trade policies</a>, impacting e-commerce platforms. Despite these headwinds, Shopify remains a significant player in the digital commerce landscape. 
Other Key Trades:
<ul>
<li>CRISPR Therapeutics AG (CRSP) &#8211; Sold 354,188 shares in ARKK.</li>
<li>Pacific Biosciences of California Inc. (PACB) &#8211; Bought 345,607 shares in ARKK.</li>
<li>10X Genomics Inc. (TXG) &#8211; Bought 184,619 shares in ARKK.</li>
<li>Kratos Defense and Security Solutions Inc. (KTOS) &#8211; Sold 75,284 shares in ARKQ and 7,842 shares via ARKX.</li>
<li>Caterpillar Inc. (CAT) &#8211; Bought 6,933 shares in ARKQ.</li>
</ul>
Benzinga Edge Stock Rankings places Palantir Momentum in the 99th percentile and Growth in the 86th percentile. How do other potent rivals compare? Find out here.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="803" height="105" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03.png" alt="" class="wp-image-896057" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03.png 803w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03-300x39.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30215237/Screenshot-2025-05-01-at-10.40.03-768x100.png 768w" sizes="(max-width: 803px) 100vw, 803px" /></figure>
Photo Courtesy: Ira Lichi on Shutterstock.com
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Equities

Markets

ETFs

ARKK

ARKW

ARKX

CRSP

KTOS

PLTR

SHOP

Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant

Biotech

General

Davos Alzheimer's Collaborative Announces PacBio Will Be A Technology Partner To Its North African Dementia Registry Project

Canaccord Genuity analyst Kyle Mikson maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Buy and maintains $3 price target.

Canaccord Genuity Maintains Buy on Pacific Biosciences, Maintains $3 Price Target

Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) on Wednesday announced preliminary revenue of $36.9 million versus a <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $33.49 million</a>.
The company said the first quarter met expectations, despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds <a href="https://www.benzinga.com/pressreleases/25/04/g44710496/pacbio-announces-preliminary-first-quarter-2025-revenue-and-reiterates-2025-revenue-guidance-of-15" target="_blank" rel="noreferrer noopener">affecting the industry</a>.
Vega system orders accelerated in the first quarter compared to the fourth quarter of 2024. The combination of system capability and its attractive price point enabled purchases from new and existing customers.
The sequencing solutions company said preliminary consumable revenue reached a company record. Annualized Revio pull-through per system was approximately $236,000. That&#8217;s in line with the company&#8217;s expectations in the low to mid $200,000s range.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44716951/enphase-rolls-out-scalable-grid-ready-iq-battery-5p-in-poland-with-15-year-warranty" rel="noreferrer noopener">Enphase Rolls Out Scalable, Grid-Ready IQ Battery 5P in Poland With 15-Year Warranty</a>
&#8220;&#8230;The Vega launch is progressing well, attracting more customers to HiFi sequencing and is expanding our addressable applications. While the funding and general macroeconomic environment is having an impact on our ability to place more instruments, particularly Revio systems at academic customers, we are encouraged by the consistent Revio utilization and annualized consumable pull-through, which remain in line with our expectations,&#8221; said Christian Henry, President and CEO of PacBio.
&#8220;We believe we are on pace to achieve the financial goals we set earlier this year. However, given the persistent uncertainty surrounding academic and NIH funding, along with the introduction of new tariffs, we are taking strategic steps to reduce spending and reinforce our plan to reach positive cash flow by the end of 2027.&#8221;
The company says it will focus on three key priorities:
<ul>
<li>Accelerating the adoption of HiFi sequencing,</li>
<li>Investing in initiatives that are targeted to improve gross margin.</li>
<li>Advancing innovation in long-read sequencing portfolio to enhance platform scalability and reduce costs.</li>
</ul>
PacBio is also restructuring commercial organization to streamline management and improve sales force efficiency.
Guidance: The company reiterates its previous 2025 revenue forecast of $155 million to $170 million versus the consensus of $161.51 million.
<ul>
<li>Growth in Vega shipments offset a year-over-year decline in Revio system shipments, with annualized pull-through per Revio system in the low to mid $200,000 range.</li>
<li>2025 non-GAAP gross margin to be between 35% and 40%.</li>
</ul>
In response to ongoing market uncertainty, PacBio is executing a plan to reduce headcount across all functions and non-headcount-related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year-end, compared to its prior guidance of $270 million to $280 million. Its ending cash and investments balance will also be higher than the previous guidance of approximately $260 million.
Price Action: PACB stock is up 8.75% at $1.31 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44715789/fda-approves-bristol-myers-opdivo-plus-yervoy-combo-for-untreated-colorectal-cancer-patients" target="_blank" rel="noreferrer noopener">FDA Approves Bristol Myers&#8217; Opdivo Plus Yervoy Combo For Untreated Colorectal Cancer Patients</a></li>
</ul>

Guidance

Health Care

Movers

Trading Ideas

Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs

U.S. stocks were higher, with the Dow Jones index surging over 300 points on Wednesday.
Shares of The Simply Good Foods Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMPL#NASDAQ">SMPL</a>) rose sharply during Wednesday's session following better-than-<a href="https://in.benzinga.com/25/04/44709659/why-packaged-food-company-simply-good-foods-stock-is-gaining-today">expected quarterly results</a>.
The company, led by CEO Geoff Tanner, reported second-quarter FY25 sales growth of 15% year-on-year to $359.65 million. It beat the analyst consensus estimate of $354.4 million. Adjusted EPS of 46 cents beat the consensus estimate of 40 cents.
The Simply Good Foods shares jumped 9.4% to $36.32 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) shares jumped 20% to $1.4399 after the company announced preliminary first quarter revenue and reiterated 2025 revenue guidance of $155 million to $170 million.</li>
<li>Peabody Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) gained 14.4% to $12.86. Shares of coal stocks traded higher after President Trump signed an executive order aimed at boosting the coal industry.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) rose 12.7% to $95.75. Maxim Group analyst Anthony Vendetti maintained Nutex Health with a Buy and raised the price target from $75 to $100.</li>
<li>Kura Sushi USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) climbed 11.9% to $46.40. Kura Sushi USA posted downbeat results for its second quarter. The company also said it sees FY25 total sales of $275 million to $279 million, versus market estimates of $280.741 million</li>
<li>IAMGOLD Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) shares gained 11.5% to $6.48. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) rose 11.1% to $14.40 amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>AngloGold Ashanti plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) jumped 10% to $36.46. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Coeur Mining, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>) rose 8% to $5.20. Shares of precious metals stocks traded higher amid strength in gold and silver. Trade war concerns and macro uncertainty could lift demand for safe-haven assets.</li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) gained 7.3% to $38.49 following upbeat quarterly results.</li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) gained 5.8% to $0.9257.</li>
<li>Urban Outfitters, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) rose 5.5% to $45.53. Citigroup analyst Paul Lejuez maintained Urban Outfitters with a Buy and lowered the price target from $65 to $54</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44709125/this-apple-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-wednesday">This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday</a></li>
</ul>
Photo via Shutterstock

Intraday Update

KRUS

NUTX

SMPL

URBN

Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday

Pacific Biosciences of California shares are trading higher after the company reported its Q1 prelimary revenue results.

In response to ongoing market uncertainty, PacBio is executing a plan to reduce both headcount across all functions and non-headcount related expenses to lower its annualized non-GAAP operating expense run-rate by $45 million to $50 million by year end in relation to its prior guidance of $270 million to $280 million. Following the reductions, PacBio aims to focus on its highest-impact long-read platform development initiatives.&nbsp;

Management

PacBio Says In Response To Ongoing Market Uncertainty, PacBio Is Executing A Plan To Reduce Both Headcount Across All Functions And Non-Headcount Related Expenses To Lower Its Annualized Non-GAAP Operating Expense Run-Rate By $45M-$50M

PacBio Sees Prelim. Q1 Revenue $36.9M, Reiterates 2025 Revenue Guidance

PacBio Appoints Jim Gibson As CFO, Effective Start Date Mar. 31

6 analysts have expressed a variety of opinions on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.04, a high estimate of $2.50, and a low estimate of $1.50. Observing a downward trend, the current average is 30.14% lower than the prior average price target of $2.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1742929238_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pacific Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
<h3>A Deep Dive into Pacific Biosciences's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pacific Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -32.79%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.04% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Pacific Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.49% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Pacific Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of 0.17%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.33, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Pacific Biosciences: Insights From 6 Financial Analysts

Scotiabank analyst Sung Ji Nam maintains Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) with a Sector Outperform and lowers the price target from $6 to $2.

Scotiabank Maintains Sector Outperform on Pacific Biosciences, Lowers Price Target to $2

On Friday, March 21, 2025, the Cathie Wood-led Ark Invest made some notable trades, including significant buys and sells.
Ark Invest's fund bought Iridium Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Pacific Biosciences of California Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) and Absci Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), while selling Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Repare Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), and Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
The IRDM Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) funds purchased a total of 68,355 shares of Iridium Communications Inc.
The total value of the shares bought, based on the last close price of $27.65, is approximately $1.89 million.
The BEAM Trade: Ark Invest&#8217;s ARKK and Ark Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) funds bought a total of 28,717 shares of Beam Therapeutics Inc.
The total value of the shares bought, based on the last close price of $23.3, is approximately $669,106.
The PACB Trade: Ark Invest&#8217;s ARKK fund bought a whopping 243,300 shares of Pacific Biosciences of California Inc.
The total value of the shares bought, based on the last close price of $1.3, is approximately $316,290.
Other Key Trades:
<ul>
<li>Illumina Inc: Ark Invest sold a total of 42,616 shares through ARKK and ARKG.</li>
<li>Absci Corp: Ark Invest&#8217;s bought 71,392 shares through ARKG.</li>
<li>Repare Therapeutics: Ark Invest sold 54,786 shares through ARKG.</li>
<li>Amgen Inc: Ark Invest sold 990 shares through ARKG.</li>
<li>Veeva Systems Inc: Ark Invest sold 1,322 shares through ARKG.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">Tesla Record Highest Trade-Ins Amid Backlash Against CEO Elon Musk, Surge In Vandalism</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

ABSI

AMGN

ARKG

ARKQ

BEAM

ILMN

IRDM

RPTX

VEEV

Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

Press Releases

PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

Jim Gibson to join PacBio as Chief Financial Officer

PacBio Grants Equity Incentive Award to New Employee

PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

Davos Alzheimer's Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer's Disease Research in North Africa

PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand

Comments

Pacific Biosciences

空売り

Pacific Biosciences (NASDAQ:PACB) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル